Aequus Pharmaceuticals (AQS) Stock Statistics & Valuation Metrics

Aequus Pharmaceuticals has a market cap or net worth of C$663.17K. The enterprise value is C$5.18M.

Aequus Pharmaceuticals has 132,634,430 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aequus Pharmaceuticals’s return on equity (ROE) is 0.34 and return on invested capital (ROIC) is -1350.65%.

The current PE Ratio of Aequus Pharmaceuticals is -0.61. Aequus Pharmaceuticals’s PEG ratio is -0.02.

In the last 12 months, Aequus Pharmaceuticals had revenue of 584.24K and earned -2.18M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -1.66M and capital expenditures 1.00, giving a free cash flow of -1.66M billion.

Aequus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Aequus Pharmaceuticals upcoming earnings date is Sep 1, 2025, TBA Not Confirmed.

Aequus Pharmaceuticals as a current ratio of 0.04, with Debt / Equity ratio of -56.73%

In the past 12 months, Aequus Pharmaceuticals has paid 0.00 in taxes.

Aequus Pharmaceuticals EV to EBITDA ratio is -4.40, with an EV/FCF ratio of -4.76.

Aequus Pharmaceuticals has C$50.24K in cash and marketable securities with C$6.61M in debt, giving a net cash position of C$6.56M billion.

Gross margin is 83.08%, with operating margin of -364.10%, and net profit margin of -372.74%.

The average price target for Aequus Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―